Table 1

Baseline characteristics of the biomarkers substudy cohort

Aixaban group
n=2473
Warfarin group
n=2377
Total substudy cohort
n=4850
Age at consent date, median (Q1, Q3)70.0 (63.0, 76.0)70.0 (62.0, 76.0)70.0 (63.0, 76.0)
Sex, female827 (33.4%)827 (34.8%)1654 (34.1%)
Sex, male1646 (66.6%)1550 (65.2%)3196 (65.9%)
AF, paroxysmal386 (15.6%)400 (16.8%)786 (16.2%)
Renal impairment, moderate/severe364 (14.8%)355 (15.0%)719 (14.9%)
Risk factors
 Congestive HF/LVEF ≤40%872 (35.3%)873 (36.7%)1745 (36.0%)
 Age≥75 years737 (29.8%)714 (30.0%)1451 (29.9%)
 Hypertension2144 (86.7%)2091 (88.0%)4235 (87.3%)
 Diabetes mellitus604 (24.4%)604 (25.4%)1208 (24.9%)
 Prior stroke/SE/TIA431 (17.4%)462 (19.4%)893 (18.4%)
 Prior MI351 (14.2%)313 (13.2%)664 (13.7%)
 PAD119 (4.8%)110 (4.6%)229 (4.7%)
CHA2DS2-VASc score
 0–1237 (9.6%)192 (8.1%)429 (8.8%)
 2535 (21.6%)496 (20.9%)1031 (21.3%)
 3641 (25.9%)652 (27.4%)1293 (26.7%)
 4539 (21.8%)519 (21.8%)1058 (21.8%)
 ≥5521 (21.1%)518 (21.8%)1039 (21.4%)
HAS-BLED score
 0–11393 (56.3%)1331 (56.0%)2724 (56.2%)
 2776 (31.4%)748 (31.5%)1524 (31.4%)
 ≥3304 (12.3%)298 (12.5%)602 (12.4%)
Medical treatment before randomisation
 Aspirin750 (30.3%)674 (28.4%)1424 (29.4%)
 Warfarin1450 (58.8%)1444 (60.9%)2894 (59.8%)
Biomarkers at baseline
 F1+2 (pmol/L), median (Q1, Q3) (n)90.2 (56.5, 149.0) (2463)88.9 (55.5, 146.0) (2365)89.5 (56.1, 148.0) (4828)
 D-dimer (µg/L), median (Q1, Q3) (n)462.0 (295.5, 752.0) (2464)452.0 (291.0, 760.0) (2366)456.0 (294.0, 754.0) (4830)
 sCD40L (µg/L), median (Q1, Q3) (n)0.56 (0.27, 1.00) (2463)0.55 (0.28, 1.10) (2366)0.55 (0.27, 1.10) (4829)
 vWF antigen (kIE/L), median (Q1, Q3) (n)1.41 (0.99, 1.87) (2461)1.42 (0.99, 1.88) (2364)1.42 (0.99, 1.88) (4825)
  • N (%) are presented if not stated otherwise.

  • AF, atrial fibrillation; HF, heart failure; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PAD, peripheral arterial occlusive disease; SE, systemic embolism; TIA, transient ischaemic attack.